Josh Gottheimer (D-NJ)· Introduced February 18, 2025

Cameron’s Law

H.R. 1414 · House bill Taxation

A Democratic bill with 11 Republican cosponsors · See all 19 cosponsors

Last activity February 18, 2025 — Referred to the House Committee on Ways and Means.

In committee

Introduced and handed to a committee in the chamber it started in.

The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.

Its path through Congress

Introduced
In Committee

What this bill would do

This bill, titled Cameron's Law'', aims to amend the Internal Revenue Code of 1986. The primary purpose is to restore the amount of the orphan drug tax credit. Specifically, it proposes to change the credit rate from 25 percent'' to ``50 percent''. This change applies to Section 45C(a) of the Internal Revenue Code. The new rate would be effective for taxable years beginning after the Act is enacted.

Yes· 3 of 6

Scored +5
Would business owners be better off under this?
Pharmaceutical company owners benefit from the increased tax credit for orphan drugs.
Scored +4
Does this put more money into medical research?
The expansion of the tax credit functions as a form of indirect funding for the research and development of orphan drugs.
Scored +4
Does this put more money into scientific research?
The increased credit incentivizes pharmaceutical research into rare diseases.

The opposite

Scored -3
Does this reduce what the federal government spends?
Increasing the tax credit rate reduces federal tax revenue.

Who it would affect, and how

Potential Positive Impacts for People

Increased Orphan Drug Tax Credit: The bill increases the tax credit amount by striking 25 percent'' and inserting 50 percent'' in Section 45C(a) of the Internal Revenue Code of 1986. This represents a restoration of the credit amount.

Groups and Interests Ranking

Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.

Healthcare: Does this put more money into medical research? — The expansion of the tax credit functions as a form of indirect funding for the research and development of orphan drugs. Does this lower the price of prescription medicines? — Increasing the tax credit for orphan drugs is intended to incentivize the development and availability of treatments for rare diseases. Does this make health care easier to get in general? — The higher tax credit may lead to increased availability of treatments for rare diseases.
Demographic And Interest Groups: Would business owners be better off under this? — Pharmaceutical company owners benefit from the increased tax credit for orphan drugs. Would high-income households be better off under this? — The increased credit provides economic benefits to pharmaceutical companies and their investors.
Education And Technology: Does this put more money into scientific research? — The increased credit incentivizes pharmaceutical research into rare diseases.
Economy And Finance: Does this reduce what the federal government spends? — Increasing the tax credit rate reduces federal tax revenue.